{
  "ticker": "IMMP",
  "company_name": "Immutep Limited",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT06128863",
      "title": "Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Neoadjuvant, Immunotherapy, Sarcoma,Soft Tissue, Radiation Therapy",
      "start_date": "2023-07-17",
      "completion_date": "2027-04-30",
      "enrollment": 0,
      "sponsor": "Maria Sklodowska-Curie National Research Institute of Oncology"
    },
    {
      "nct_id": "NCT04252768",
      "title": "A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel",
      "status": "WITHDRAWN",
      "phase": "PHASE1",
      "condition": "Metastatic Breast Cancer",
      "start_date": "2023-06",
      "completion_date": "2026-02",
      "enrollment": 0,
      "sponsor": "Immutep S.A.S."
    },
    {
      "nct_id": "NCT01308294",
      "title": "Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients",
      "status": "TERMINATED",
      "phase": "PHASE1, PHASE2",
      "condition": "Melanoma",
      "start_date": "2010-06",
      "completion_date": "2014-04",
      "enrollment": 0,
      "sponsor": "Centre Hospitalier Universitaire Vaudois"
    },
    {
      "nct_id": "NCT02614833",
      "title": "IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Adenocarcinoma Breast Stage IV",
      "start_date": "2015-12",
      "completion_date": "2021-05",
      "enrollment": 0,
      "sponsor": "Immutep S.A.S."
    },
    {
      "nct_id": "NCT00349934",
      "title": "IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Metastatic Breast Cancer",
      "start_date": "2006-07",
      "completion_date": "2010-01",
      "enrollment": 0,
      "sponsor": "Immutep S.A.S."
    },
    {
      "nct_id": "NCT00354861",
      "title": "A Randomized Phase I Study of a Hepatitis B Antigen Combined With IMP321",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy",
      "start_date": "2005-05",
      "completion_date": "2006-02",
      "enrollment": 0,
      "sponsor": "Immutep S.A.S."
    },
    {
      "nct_id": "NCT00351949",
      "title": "IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC)",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Stage IV Renal Cell Carcinoma",
      "start_date": "2005-09",
      "completion_date": "2008-10",
      "enrollment": 0,
      "sponsor": "Immutep S.A.S."
    },
    {
      "nct_id": "NCT06726265",
      "title": "Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)",
      "start_date": "2025-03-21",
      "completion_date": "2029-09",
      "enrollment": 0,
      "sponsor": "Immutep S.A.S."
    },
    {
      "nct_id": "NCT06637865",
      "title": "A First-in-human Study of the Safety of an Immunosuppressive Antibody (IMP761) in Healthy Volunteers",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Healthy",
      "start_date": "2024-07-17",
      "completion_date": "2026-04",
      "enrollment": 0,
      "sponsor": "Immutep S.A.S."
    },
    {
      "nct_id": "NCT07102940",
      "title": "Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer",
      "status": "NOT_YET_RECRUITING",
      "phase": "PHASE2",
      "condition": "Breast Cancer, HER 2 Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer, Stage 1-3",
      "start_date": "2026-01-02",
      "completion_date": "2028-08",
      "enrollment": 0,
      "sponsor": "George Washington University"
    }
  ],
  "summary": {
    "total_trials": 17,
    "by_phase": {
      "PHASE2": 5,
      "PHASE1": 8,
      "PHASE1, PHASE2": 2,
      "PHASE3": 1,
      "PHASE2, PHASE3": 1
    },
    "by_status": {
      "ACTIVE_NOT_RECRUITING": 2,
      "WITHDRAWN": 1,
      "TERMINATED": 2,
      "COMPLETED": 8,
      "RECRUITING": 3,
      "NOT_YET_RECRUITING": 1
    },
    "active_trials": 5,
    "completed_trials": 8,
    "conditions": [
      "Adenocarcinoma Breast Stage IV",
      "Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)",
      "Breast Cancer, HER 2 Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer, Stage 1-3",
      "Breast Carcinoma",
      "HNSCC",
      "Healthy",
      "Melanoma",
      "Metastatic Breast Cancer",
      "NSCLC, HNSCC",
      "Neoadjuvant, Immunotherapy, Sarcoma,Soft Tissue, Radiation Therapy",
      "Solid Tumors, Peritoneal Carcinomatosis, NSCLC Adenocarcinoma, Urothelial Carcinoma",
      "Stage IV Melanoma, Stage III Melanoma",
      "Stage IV Renal Cell Carcinoma"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:19:00.247535",
    "search_query": "Immutep Limited",
    "url": "https://clinicaltrials.gov/search?term=Immutep+Limited"
  }
}